Since I was diagnosed with idiopathic pulmonary fibrosis (IPF) in April 2016, I have enjoyed connecting with other patients living with this life-threatening lung disease. For the most part, hearing others’ stories has given me comfort, hope, and encouragement. I believe that the benefits of connecting with my…
BML‐111, a potent activator of the natural anti-inflammatory lipoxin A4 receptor, protects lungs from fibrosis by inhibiting fibroblast activation and decreasing the levels of inflammatory signaling molecules, a mouse study shows. The study “BML-111 suppresses TGF-β1-induced lung fibroblast activation in vitro and decreases experimental pulmonary fibrosis in vivo” was…
I don’t know about you, but I’m continually aware of my limited time on this earth. Using my time wisely is very important to me. I’ve been working on several goals that have been a challenge to finish. I thought I’d share one I recently completed and what…
Results from the long-term PASSPORT clinical study are consistent with the known safety profile of Esbriet (pirfenidone), further strengthening the safety of the therapy in patients with idiopathic pulmonary fibrosis (IPF). After authorization by the European Medicine Agency (EMA), it was suggested that a large, long-term post-authorization study be conducted…
As I reflect on this past month, I am happy to share that October has been filled with many good times and memories for my loved ones and me. As we’re only a couple of months away from wrapping up 2018, I look forward to reflecting on this…
Galapagos has launched a Phase 2 trial testing the safety and effectiveness of their investigational new therapy called GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF), reporting that the first participant has now received the therapy. GLPG1205 is an anti-inflammatory small molecule that specifically inhibits GPR84, a protein that promotes…
Treatment with Ofev (nintedanib) offers less clinical benefit to patients with severe idiopathic pulmonary fibrosis (IPF) than to those with mild-to-moderate disease, but does improve outcomes if these patients are able to continue on treatment over the longer term, a new study shows. Controlling the therapy’s side effects will be essential…
The incidence of lung cancer is greater among patients with idiopathic pulmonary fibrosis (IPF), compared with the general population, and is associated with a worse prognosis, a new U.S. study reports. The study, “Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease –…
My 95-year-old father died last week. He’d been battling cancer on and off for the last eight years. He was a wonderful father and grandfather. I’m so blessed to have had him as my dad for so long. I miss him so.
Galecto Biotech is planning a new international Phase 2/3 clinical trial to evaluate inhaled TD139, its investigational candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF). The design of the study, which will be conducted at several clinical centers across Europe and North America, has already been…
Get regular updates to your inbox.
